$27.080
+1.847 (+6.82%)收盤時
PBLS 資訊
PBLS 事件
Parabilis Medicines Stock Rises 6.3% to $29.20
Parabilis Medicines is up 6.3%, or $1.72 to $29.20.
Parabilis Medicines Shares Drop 12.5% to $36.51
Parabilis Medicines is down -12.5%, or -$5.22 to $36.51.
Parabilis Medicines Appoints Craig Tendler to Board of Directors
Parabilis Medicines announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside his board responsibilities. Tendler brings more than 30 years of experience in oncology drug development and medical affairs, including two decades at Johnson & Johnson, where he most recently served as global head of late-stage clinical development and global medical affairs for oncology. Tendler currently serves on the board of directors of TuHURA Biosciences and Predicta Biosciences and as a scientific advisor for several biotechnology companies. He is also an alternate industry representative to the FDA's Oncologic Drugs Advisory Committee.
Parabilis Medicines Q2 Revenue $148K, Misses Consensus $16.67M
Reports Q2 revenue $148,000, consensus $16.67M. "This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon(TM) platform through our strategic research collaboration with Regeneron focused on developing Antibody-Helicon Conjugates," said Mathai Mammen, M.D., Ph.D., Chairman, President and Chief Executive Officer of Parabilis Medicines.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。